/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

ZENTALIS PHARMACEUTICALS INC Share Price Today: Live Updates & Key Insights

ZENTALIS PHARMACEUTICALS INC share price today is $2.73, up -7.09%. The stock opened at $2.81 against the previous close of $2.96, with an intraday high of $2.91 and low of $2.745.

ZENTALIS PHARMACEUTICALS INC Share Price Chart

style
pb-0

ZENTALIS PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

ZENTALIS PHARMACEUTICALS INC Share Price Performance

$2.73 -0.0709(-7.09%) ZNTL at 13 Mar 2026 04:01 PM Biotechnology
Lowest Today 2.745
Highest Today 2.91
Today’s Open 2.81
Prev. Close 2.96
52 Week High 3.95
52 Week Low 1.01
Day’s Range: Low 2.745 High 2.91
52-Week Range: Low 1.01 High 3.95
1 day return -
1 Week return +19.82
1 month return +14.58
3 month return +97.13
6 month return +89.0
1 year return +51.93
3 year return -83.73
5 year return -93.99
10 year return -

ZENTALIS PHARMACEUTICALS INC Institutional Holdings

Matrix Capital Management Company, LLC 21.56

5AM Venture Management, LLC 6.10

Renaissance Technologies Corp 4.45

Vanguard Group Inc 4.41

Acadian Asset Management LLC 4.39

Citadel Advisors Llc 3.21

Vanguard Total Stock Mkt Idx Inv 2.62

D. E. Shaw & Co LP 2.56

TANG CAPITAL MANAGEMENT LLC 2.39

Bank of America Corp 2.39

Two Sigma Advisers, LLC 2.29

Two Sigma Investments LLC 2.27

JPMorgan Chase & Co 2.23

Morgan Stanley - Brokerage Accounts 2.17

Opaleye Management Inc 2.16

Decheng Capital LLC 2.04

Ishara Investments LP 2.04

BlackRock Inc 1.93

GSA Capital Partners LLP 1.81

Tybourne Capital Management (HK) Ltd 1.48

PRIMECAP Management Company 1.48

PRIMECAP Odyssey Aggressive Growth 1.04

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Fidelity Extended Market Index 0.41

Vanguard US Opportunities Ins USD Acc 0.40

Fidelity Enhanced Small Cap ETF 0.35

Vanguard Strategic Small-Cap Equity Inv 0.32

Invesco RAFI US 1500 Small-Mid ETF 0.29

Sun Life Global Mid Cap Fund I 0.26

iShares Micro-Cap ETF 0.24

Vanguard Health Care ETF 0.24

Blackrock Extended Mkt Fund CF 0.20

Extended Equity Market Fund K 0.17

Fidelity Total Market Index 0.15

Fidelity Series Total Market Index 0.12

Bridgeway Ultra-Small Company Market 0.12

Spartan Extended Market Index Pool F 0.12

Northern Trust Extended Eq Market Idx 0.10

NT Ext Equity Mkt Idx Fd - L 0.10

Dimensional US Small Cap ETF 0.08

ZENTALIS PHARMACEUTICALS INC Market Status

Strong Buy: 3

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

ZENTALIS PHARMACEUTICALS INC Fundamentals

Market Cap 191.66 M

PB Ratio 0.7579

PE Ratio 0.0

Enterprise Value -52.33 M

Total Assets 430.34 M

Volume 569114

ZENTALIS PHARMACEUTICALS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-286245000 -286.2M, FY22:-220831000 -220.8M, FY21:-164262000 -164.3M, FY20:-118548000 -118.5M, FY19:-46378000 -46.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-160000 -0.2M, Q1/2025:-262000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-327000 -0.3M

Quarterly Net worth Q3/2025:-26691000 -26.7M, Q2/2025:-26874000 -26.9M, Q1/2025:-48279000 -48.3M, Q3/2024:-40158000 -40.2M, Q2/2024:-88277000 -88.3M

About ZENTALIS PHARMACEUTICALS INC & investment objective

Company Information Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 166

Industry Biotechnology

CEO Ms. Julie M. Eastland M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow